bioAffinity Technologies Raises $4M in At-the-Market Offering to Fuel Lung Cancer Test Expansion

  • bioAffinity Technologies closed a $4M registered direct offering of common stock at $6.122 per share
  • Concurrent private placement included warrants for up to 980,072 shares at the same exercise price
  • Proceeds will support working capital and sales growth for CyPath® Lung, its noninvasive lung cancer test
  • Offering conducted under Nasdaq at-the-market rules and SEC Form S-3 registration
  • WallachBeth Capital served as sole placement agent for the transaction

This $4M raise positions bioAffinity to scale its noninvasive lung cancer diagnostic amid growing demand for early detection solutions. The at-the-market structure suggests strategic flexibility in capital deployment, while the focus on working capital highlights near-term commercialization priorities. The transaction comes as biotech investors increasingly scrutinize diagnostic companies' ability to demonstrate clinical utility and reimbursement pathways.

Commercial Execution
How effectively bioAffinity can convert this capital into CyPath Lung sales growth
Market Positioning
Whether the company can differentiate CyPath Lung in the competitive lung cancer diagnostics space
Regulatory Dynamics
The pace at which CLIA oversight might evolve and impact LDT offerings like CyPath Lung